

### **REMARKS**

Claims 2-15 are pending and under consideration. Claims 16-22 have been added. After entry of the present Amendment, claims 2-22 will be pending and under consideration. The newly added claims submitted herewith are supported by the specification and original claims and do not add new matter. Newly added claim 16 is supported, for example, by Example 4. Newly added claims 17-21 are supported, for example, by Example 5. Furthermore, the recitation in newly added claims 17, 20, and 21 regarding position 506 of factor V is supported, for example, by page 6, last paragraph. Newly added claim 22 is supported, for example, by Example 4, which indicates that heparin addition did not alter the interpretation of test results even without neutralization.

As indicated above, the new claims submitted herewith are supported by the specification and original claims and do not add new matter. The new claims do not require a new search or raise new issues for consideration because they merely address issues already raised by the Examiner or define Applicants' invention more clearly. It is submitted that the new claims are in condition for allowance or in better condition for appeal by reducing the number of issues for consideration on appeal. The new claims were not presented earlier in the prosecution because it is maintained that the previously pending claims were allowable. Since the new claims do not add new matter or require a new search or consideration, and place the claims in condition for allowance or in better condition for appeal, entry of the new claims is respectfully requested and reconsideration of the pending claims in view of the remarks herein are respectfully requested.

### **Rejection Under 35 U.S.C. § 102(a)**

The rejection of claims 2-15 under 35 U.S.C. § 102(a) as allegedly anticipated by Sun et. al. (*Blood*, 83, 3120, 1994), is respectfully traversed. To anticipate an invention, each and every element of a claim must be found in a single prior art reference. MPEP § 2131; *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628,631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987). In determining that quantum of prior art disclosure which is necessary to declare an

applicant's invention "not novel" or "anticipated" within section 102, the stated test is whether a reference contains an "enabling disclosure." MPEP § 2121.01 citing In re Hoeksema, 399 F.2d 269, 158 USPA 596 (CCPA 1968).

The Office Action cites the reasons for rejection in the Office Action mailed December 17, 2002 and indicates that the Applicants arguments in the Response filed April 17, 2003 were not convincing because they allegedly presented none of the arguments, exhibits, or other considerations that led to the withdrawal of the Sun et al. reference in the parent file for the present application. The Office action maintains the allegation that the APC concentration and calcium concentrations are within the range of the pending claims.

Applicant's respectfully assert that the invention, as recited in claim 2, from which the remaining pending claims depend, distinguishes over Sun et al. by being directed to a method for diagnosing a subject as having, or at risk for having, a thrombotic disorder, wherein the subject is presently on an oral anticoagulant regimen. Although Sun et al. mention that the protocols disclosed therein "*could* allow assays for abnormal APC-resistant factors Va or VIIIa for patients on oral anticoagulants or heparin, after heparin neutralization," (emphasis added), Sun et al. do not enable performing the method on subjects who are on an oral anticoagulant regimen because they do not actually perform experiments to establish that heparin or other anti-coagulants would not interfere with the assay. A skilled artisan could not expect success on samples from subjects on anti-coagulant therapy because without actually performing the experiment it could not be determined whether heparin present in concentrations of 5-30% of those in a subject's plasma would interfere with the method. The two subjects analyzed in Sun et al., designated "LS" and "BB," (Sun et al., page 3120, right column, first paragraph "MATERIALS AND METHODS") were among a group of patients that were selected because they were not on anti-coagulant therapy (Griffin et al., Blood, 82:1989-1993, 1989 right column, (1993)) (Exhibit A). Accordingly, Sun et al. not only do not enable the claimed invention, they actually teach away from the present invention by teaching that the methods disclosed therein should be performed on patients who are not on anti-coagulant therapy.

Accordingly, Applicants respectfully request withdrawal of the rejection of claims 2-15 under 35 U.S.C. § 102(a).

Regarding newly added claim 22, Applicants assert that this claim is further distinguishable over Sun et al. because Sun et al. in its brief mention regarding performing an assay on samples from patients on heparin indicates that the method would be performed after heparin neutralization.


Regarding newly added claims 17-21, Applicants assert that the newly added claims are further distinguishable over Sun et al. because Sun et al. is silent as to comparing results of a test reaction with and without APC, wherein a clotting time for the test reaction with APC that is similar to, or faster than a clotting time for the no-APC reaction is indicative of a thrombotic disorder associated with APC-resistant factor V or Va. Sun et al. in an analysis of activated partial thromboplastin time (APTT) with and without APC, illustrate that even with only APC resistant plasma, APTT is almost twice as long in the presence versus absence of APC (Figure 5 of Sun et al.). Furthermore, certain new claims are even more distinguishable over Sun et al. by indicating that the similar or faster clotting time with APC indicates a thrombotic disorder associated with a homozygous mutation in factor V or Va rendering the factor APC-resistant (claim 19), wherein the mutation occurs at position 506 of factor V (claim 20), and wherein the mutation is a change from arginine to glutamine at position 506 of factor V (claim 21). Sun et al. does not present results of patients that are homozygous factor V or Va mutants.

**CONCLUSION**

In view of the above remarks, reconsideration and favorable action on all claims are respectfully requested. In the event any matters remain to be resolved, the Examiner is requested to contact the undersigned at the telephone number given below so that a prompt disposition of this application can be achieved.

Respectfully submitted,

Date: September 3, 2003



Lisa A. Haile, J.D., Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
**USPTO Customer Number 28213**

Application No.: 09/606,779

Applicant: Griffin, et. al.

Filed: June 28, 2000

PATENT

Attorney Docket No.: SCRIP1180-3

Exhibit A - Page 1

**EXHIBIT A**

Copy of Griffin et al., *Blood*, 82:1989-1993 (1993).

## Anticoagulant Protein C Pathway Defective in Majority of Thrombophilic Patients

By John H. Griffin, Bruce Evatt, Carol Wideman, and José A. Fernández

A defect involving poor anticoagulant response to activated protein C (APC), an anticoagulant serine protease known to inactivate factors Va and VIIIa in plasma, was recently reported and the existence of a novel APC cofactor was suggested. To define the frequency of this defect among 25 venous thrombophilic patients with no identifiable laboratory test abnormality and among 22 patients previously identified with heterozygous protein C or protein S deficiency, the APC-induced prolongation of the activated partial thromboplastin time assay for these patients was compared with results for 35 normal subjects.

**T**HROMBOPHILIA can be defined as a tendency toward venous thromboembolic disease in adults under 50 years old in the absence of known risk factors including, among others, malignancy, immobilization, or major surgery. In principle, a tendency toward venous thrombosis could arise from hyperactive coagulation pathways, hypoactive anticoagulant mechanisms, or hypoactive fibrinolysis. Molecular explanations for some thrombophilic patients came following the discoveries of hereditary thrombophilia associated with deficiencies of the anticoagulant factors, antithrombin III,<sup>1,2</sup> protein C,<sup>3-5</sup> and protein S.<sup>6,7</sup> Studies of relative frequencies of deficits in these factors and several other coagulation and fibrinolytic factors showed that deficiencies of protein C, protein S, and antithrombin III are the most frequently demonstrable abnormalities. Moreover, collectively these three deficiencies are present in 9% to 21% of thrombophilic patients, with estimates of a deficiency of each of these three factors ranging from 2% to 9%.<sup>8-13</sup> The frequency of other coagulation or fibrinolytic factor deficiencies is smaller than any of these three factors. Thus, no molecular abnormality has been identified in the large majority (60% to 80%) of thrombophilic patients. Recently Dahlback et al<sup>14</sup> characterized a hereditary defect in the plasmas of three unrelated thrombophilic patients<sup>14</sup> who gave a poor anticoagulant response to activated protein C (APC), an anticoagulant serine protease known to inactivate factors Va and VIIIa in plasma.<sup>15</sup> Moreover, further experiments suggested the existence of a previously unknown APC cofactor that was deficient in these three probands.<sup>14</sup> The present study was performed to define the frequency of this new deficit among thrombophilic patients and among patients previously identified with heterozygous protein C or protein S type I deficiency. The results show that this new defect in anticoagulant response to APC is surprisingly present in the majority of previously undiagnosed thrombophilia cases but is not present in most heterozygous type I deficient protein C or protein S patients. The results demonstrate that abnormalities in the anticoagulant protein C pathway are present in the majority of thrombophilic patients.

### MATERIALS AND METHODS

A panel of 25 unrelated patients (17 females and 8 males) with histories of venous thrombosis was evaluated for abnormal antico-

agulant response to APC. This panel represented all eligible patients among a total of 75 patients (34 females and 41 males) referred between January 1, 1986 and May 31, 1993 to the Centers for Disease Control Hemostasis Reference Laboratory in Atlanta for evaluation of plasma protein abnormalities associated with thrombotic disease. Criteria for exclusion from the evaluation described here was based on the following: 8 were excluded because of arterial not venous thrombosis or because of the presence of ongoing thrombosis; 20 were excluded because of diagnosis of protein C, protein S, or antithrombin III deficiency or the presence of a lupus anticoagulant; and 22 (7 females and 15 males) were excluded for being on anticoagulant therapy, because the prolongation of the activated partial thromboplastin time (APTT) caused by APC requires that patients have a normal APTT value. Thus, one third of all patients (25 of 75) referred during the 1986-1993 period were further evaluated in our study. All but 3 of the 25 patients had been asymptomatic for at least 3 months at the time of testing. Three patients were tested between 2 and 4 weeks after a thrombotic episode. All patients studied had no evidence of a lupus anticoagulant and all assay values for each patient were within the normal ranges for protein C activity, protein S anticoagulant cofactor activity, protein C antigen, total and free protein S antigen, antithrombin III activity, plasminogen activity, clottable fibrinogen levels, and thrombin time assays as determined using standard assay methods performed as previously summarized.<sup>16</sup> The mean age at first episode of venous thrombosis was 29.6 years old (range 17 to 50) and the mean age at time of blood sampling was 39.8 years old. The spectrum of venous thrombotic symptoms of these patients, mainly involving deep vein thrombosis, pulmonary emboli, and thrombophlebitis, was typical

© 1993 by The American Society of Hematology.

agulant response to APC. This panel represented all eligible patients among a total of 75 patients (34 females and 41 males) referred between January 1, 1986 and May 31, 1993 to the Centers for Disease Control Hemostasis Reference Laboratory in Atlanta for evaluation of plasma protein abnormalities associated with thrombotic disease. Criteria for exclusion from the evaluation described here was based on the following: 8 were excluded because of arterial not venous thrombosis or because of the presence of ongoing thrombosis; 20 were excluded because of diagnosis of protein C, protein S, or antithrombin III deficiency or the presence of a lupus anticoagulant; and 22 (7 females and 15 males) were excluded for being on anticoagulant therapy, because the prolongation of the activated partial thromboplastin time (APTT) caused by APC requires that patients have a normal APTT value. Thus, one third of all patients (25 of 75) referred during the 1986-1993 period were further evaluated in our study. All but 3 of the 25 patients had been asymptomatic for at least 3 months at the time of testing. Three patients were tested between 2 and 4 weeks after a thrombotic episode. All patients studied had no evidence of a lupus anticoagulant and all assay values for each patient were within the normal ranges for protein C activity, protein S anticoagulant cofactor activity, protein C antigen, total and free protein S antigen, antithrombin III activity, plasminogen activity, clottable fibrinogen levels, and thrombin time assays as determined using standard assay methods performed as previously summarized.<sup>16</sup> The mean age at first episode of venous thrombosis was 29.6 years old (range 17 to 50) and the mean age at time of blood sampling was 39.8 years old. The spectrum of venous thrombotic symptoms of these patients, mainly involving deep vein thrombosis, pulmonary emboli, and thrombophlebitis, was typical

*From the Department of Molecular and Experimental Medicine and Committee on Vascular Biology, The Scripps Research Institute, La Jolla CA; and Centers for Disease Control and Prevention, Atlanta, GA.*

*Submitted July 21, 1993; accepted July 26, 1993.*

*Supported in part by the National Institutes of Health Grant No. HL-31950 and M01RR00833, and the Rose Stein Charitable Trust, La Jolla, CA.*

*Address reprint requests to John H. Griffin, PhD, The Scripps Research Institute, 10666 Torrey Pines Rd, SCR-5, La Jolla, CA 92037.*

*The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.*

© 1993 by The American Society of Hematology.  
0006-4971/93/8207-0041\$3.00/0

of groups of thrombophilic patients previously described.<sup>8-13</sup> Of the 25 patients, 13 have a family history positive for venous thrombosis and 12 had apparently a negative history. Patients' frozen plasma samples that had been stored at  $-70^{\circ}\text{C}$  for periods ranging from 1 week to 7 years were studied.

Normal subjects were comprised of healthy adults between 21 and 50 years old who were not taking any medications. To assess the effects of frozen storage of plasma on the APC anticoagulant response, two panels of normal subjects' plasmas were used. For the first group of normals (eight females and eight males), plasma samples that had been stored frozen at  $-80^{\circ}\text{C}$  for 2 years were used, whereas for the second group (10 females and 9 males), plasma samples that had been stored frozen for 9 years at  $-80^{\circ}\text{C}$  were used.

Twelve protein C type I heterozygous deficient patients from 10 kindreds and 10 type I protein S heterozygous deficient patients from eight kindreds, all of whom except one protein C deficient patient, who had one or more episodes of venous thrombosis before 50 years of age were studied. The protein C deficient patients (five females and seven males) had a mean protein C antigen of 46% (range 34% to 62%) and a mean protein S antigen of 112% (range 77% to 135%), whereas protein S deficient patients (six females and four males) had a mean protein S antigen level of 56% (range 44% to 65%) and a mean protein C antigen level of 99% (range 82% to 116%).

The assay for anticoagulant response to APC used APTT assays with minor modifications from those previously described.<sup>14</sup> APTT assays, using the Stago ST4 coagulometer (Diagnostica Stago, Asnières, France), were performed as follows: 50  $\mu\text{L}$  of APTT reagent (Platelin Excel LS; Organon Teknika, Durham, NC) was mixed with 50  $\mu\text{L}$  of plasma and incubated for 5 minutes at  $37^{\circ}\text{C}$  before recalcification by addition of 50  $\mu\text{L}$  of a solution containing 30 mmol/L  $\text{CaCl}_2$  in Tris-buffered saline containing bovine serum albumin<sup>14</sup> either with or without 16 nmol/L APC, and the clotting time was measured. Purified human APC (greater than 95% pure) was provided by Dr Andras Gruber (The Scripps Research Institute).

## RESULTS

The anticoagulant response to the anticoagulant enzyme APC was determined for a panel of 25 unrelated thrombophilic patients and compared with results for 35 normal subjects of comparable age based on APTT assays that were performed without and with the addition of APC in the recalcification reagent.<sup>14</sup> For the APTT assays without APC, the patients' mean value was 34.5 seconds (2 SD = 9.9 seconds) compared with 35.0 seconds (2 SD = 7.9 seconds) for the 35 normals. No significant difference in APTT was observed between the patients and normals or between the two panels of normals, which differed only in length of time that their plasmas had been stored frozen, ie, 2 years versus 9 years. Figure 1 presents values for the net calculated prolongation in APTT because of APC, simply defined as the APTT value in the presence of APC minus the APTT value in the absence of APC. The observed mean APC-induced prolongation for 35 normals was 88.8 seconds, whereas the mean value for 25 thrombophilic patients of 42.2 seconds was very much shorter ( $P < 9.7 \times 10^{-7}$ ). Values for normals but not for patients could be fit by a single log-normal distribution (data not shown). Remarkably, six patients (four females and two males) had values ( $<20$  seconds) much lower than the lowest of the 35 normals (40 seconds) and nine patients (seven females and two males) had low values between 30 to 39 seconds with the result that 15 of 25 patients




Fig 1. Propagation of APTT induced by APC for 35 normal subjects and for 25 thrombophilic patients.

(60%) had an APC-induced APTT prolongation that was below all of the 35 normals. Sixteen of 25 patients (68%) had a prolongation that was below the value (42.3 seconds) observed for 97% of the normal subjects (Fig 1). Of these 16 deficient patients (11 females and 5 males), 8 had positive family histories for thrombosis, whereas 8 had apparently negative histories. Overall, 14 of the 25 patients had a positive family history. For the 16 deficient patients, neither the gender distribution nor the presence of a positive family history of venous thrombosis differed significantly from the group of 25 patients.

The ratio of the APTT with APC to the APTT without APC was calculated and this parameter was compared with values for the APC-induced APTT prolongation (Fig 2). There was an excellent correlation between these parameters for the 35 normals ( $r = 0.80$ ). This APTT ratio value was extremely low ( $<1.7$ ) for six patients and was low for seven other patients, ie, below the lowest observed normal value (2.15) for any of the 35 normals. Thus, 13 of 25 patients (52%) had APTT ratio values below the lowest observed normal value. In Fig 2, the two dashed lines indicate the lowest observed values for the 35 normals for the APC-induced APTT prolongation (40 seconds) or for the ratio (2.15). Twelve of 25 patients (48%) had values in the lower-left quadrant, ie, below both the lowest prolongation and ratio values, whereas three patients had prolongation values  $<40$  seconds but ratio values  $>2.15$  (2.26, 2.27, and 2.28, respectively) and one patient had a ratio value  $<2.15$  but a prolongation  $>40$  seconds (41.7 seconds). Overall, 16 of 25




Fig 2. Comparison of APC-induced prolongation of APTT to the ratio of the APTT value in the presence of APC to that for the absence of APC for normal and thrombophilic subjects.

patients (64%) had values outside the upper-right quadrant (Fig 2) and must be considered outside the normal range for anticoagulant response to APC. Thus, abnormal anticoagulant response to APC is demonstrable in 64% of this panel of 25 unrelated thrombophilic patients.

To assess whether this defect in anticoagulant response to APC was present in patients with heterozygous protein C or protein S deficiency, 12 heterozygous protein C deficient and 10 heterozygous protein S deficient patients were studied. The APC-dependent prolongation of the APTT was within the normal range for 20 of these 22 subjects. The mean value of APTT prolongation for the 12 protein C deficient patients was 100 seconds and for the 10 protein S deficient patients was 77 seconds. One protein C deficient male patient who had a low prolongation value of 4 seconds (APTT ratio = 1.1) and one protein S deficient female patient had a prolongation value of 31 seconds (APTT ratio = 1.9) were identified. Thus, the increased thrombotic risk in this group of patients associated with low protein C or protein S levels is not usually compounded by any apparent defect in anticoagulant response to APC, although 2 of these 22 patients interestingly had an abnormal response to APC. Moreover, because the APC-dependent prolongation of the APTT was normal in heterozygous protein S deficient plasmas, it seems that normal levels of protein S are not particularly important for the anticoagulant effects of APC in the APTT assay performed as described.

Mixing of normal pooled plasma with each of two extremely defective plasmas (APC-induced prolongation of APTT <20 seconds) was performed and the APTT assays were made to assess the ability of normal plasma to correct the poor response of the defective plasmas. The results in Fig 3 were similar to those of Dahlbäck et al<sup>14</sup> and suggest

that normal plasma contains a factor missing from these patients' plasmas. To assess whether the same factor was missing from the other deficient plasmas, mixing experiments using the six severely deficient plasmas that had APC-dependent prolongations of less than 20 seconds (Fig 1) were performed. For this purpose the ability of APC to prolong the APTT of mixtures containing one part of patient LS's plasma (see Fig 3 legend) and three parts of the other patient's plasma was determined. The results (data not shown) showed no cross-correction of the clotting assay abnormality in any of the mixtures ( $\pm 3$  seconds), suggesting that these six defective plasmas were missing the same factor. The ability of normal plasma to correct the assay defect of each of these six plasmas was demonstrated by assaying mixtures containing patient and normal plasmas. The results showed that normal plasma corrected the clotting assay defect of each plasma; for example, the observed APTT prolongations caused by APC for these six patients' plasma mixed with normal plasma (one part patient plasma plus three parts normal plasma) were 63 seconds (patient BB), 71 seconds (patient LS), 67, 70, 77, and 82 seconds, compared with 87 seconds for neat normal plasma. Thus, the clotting assay abnormality of each of these six plasmas was similarly corrected by normal plasma.

#### DISCUSSION

This study confirms and extends the report of Dahlbäck et al<sup>14</sup> showing a poor anticoagulant response to APC in plasmas from thrombophilic patients. The remarkably high frequency of this defect is 52% to 64% of all previously undiagnosed thrombophilic patients, depending on whether the APC-induced APTT prolongation or ratio of APTT val-






Fig 3. Correction by normal plasma of the abnormal APTT in the presence of APC of two plasmas defective in anticoagulant response to APC (patient BB [circles] and patient LS [triangles]).

ues with versus without APC or both are used as diagnostic parameters. Neither of these two parameters seemed more useful than the other in this limited study, and it is noted that each of these parameters will likely vary in absolute value depending on the assay conditions, ie, depending on APTT-activating reagent, APC concentration, plasma dilution, etc. Careful standardization of any set of reagents and reaction conditions to establish the normal range will be essential to use a particular assay.

Mixing experiments using patient and normal plasmas in various combinations showed that the six severely defective plasmas did not cross-correct each other, suggesting that each plasma has the same molecular defect. The defect in each of the six severely abnormal patient plasmas was similarly corrected by normal plasma. Moreover, the dose-response for the correction of defective plasmas by various relative amounts of normal plasma supports the hypothesis that there is an anticoagulant factor or cofactor present in normal plasma but missing from the defective plasmas. Whether this missing factor is actually an "APC cofactor" or perhaps an anticoagulant factor whose action is synergistic with the action of APC remains to be clarified following the purification, characterization, and definition of mechanism of action of this novel anticoagulant factor. What is certain is that this factor markedly affects the expression of APC anticoagulant activity and is hence a contributor to the protein C pathway. Thus, the results here, together with previous data indicating that previously the most likely identifiable molecular abnormalities in thrombophilia involve protein C and protein S deficiency,<sup>8-13</sup> demonstrate that the anticoagulant protein C pathway is defective in the majority of thrombophilic patients.

Because 20 of 22 patients with either heterozygous protein C or protein S deficiency had normal values for the APC-induced prolongation of the APTT assay, this new defect is not associated with thrombotic risk in most protein C or protein S deficient patients and the new defect seems to be an independent risk factor for venous thrombosis. Nonetheless, it is notable that one protein C deficient patient and one protein S deficient patient seemed defective in the hypothesized APC cofactor, suggesting these two patients may have deficiencies in two independent risk factors.

The APC-induced prolongation of the APTT assay used here is reminiscent of the recently reported assay<sup>17</sup> involving the APC-induced inactivation of endogenous factor VIII in the plasmas of patients with a lupus anticoagulant. Based on this latter assay it was reported that plasmas from lupus anticoagulant patients with thrombosis gave a poor response to APC and that patients with thrombosis could thereby be distinguished from those without thrombosis.<sup>17</sup> There may be a relationship between these findings<sup>17</sup> and the results here and elsewhere,<sup>14</sup> and we speculate that auto-antibodies against the new hypothesized APC cofactor may play a role in the risk of thrombosis among patients with lupus anticoagulants.

It is tempting to speculate that an acquired deficiency of the new APC cofactor could be associated with an acquired risk of thrombosis in a variety of clinical settings. Purification and characterization of the new factor will lead to new tests to assess this possibility and also potentially lead to therapy using this new anticoagulant factor just as the therapeutic use of purified protein C<sup>18,19</sup> followed the discovery of protein C deficiency associated with thrombophilia.<sup>3-5</sup>

#### ACKNOWLEDGMENT

We gratefully acknowledge the excellent skillful technical assistance of Beth Samuelson.

#### REFERENCES

1. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. *Thromb Diath Haemorrh* 13:516, 1965
2. Thaler E, Lechner K: Antithrombin III deficiency and thromboembolism. *Clin Haematol* 10:369, 1981
3. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C: Deficiency of protein C in congenital thrombotic disease. *J Clin Invest* 68:1370, 1981
4. Branson HE, Katz I, Marble R, Griffin JH: Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. *Lancet* 2:1165, 1983
5. Seligsohn U, Berger A, Abead M, Rubin L, Attias D, Zivelin A, Rapaport SJ: Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. *N Engl J Med* 310:559, 1984
6. Comp PC, Esmon CT: Recurrent venous thromboembolism patients with a partial deficiency of protein S. *N Engl J Med* 311:1525, 1984

7. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH: Plasma protein S deficiency in familial thrombotic disease. *Blood* 64:1297, 1984
8. Gladson CL, Griffin JH, Hach V, Beck KH, Scharer I: The incidence of protein C and protein S deficiency in young thrombotic patients. *Blood* 66:350a, 1985 (suppl 1, abstr)
9. Gladson CL, Scharer I, Hach V, Beck KH, Griffin JH: The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. *Thromb Haemost* 59:18, 1988
10. Briet E, Engesser L, Brommer EJP, Broekmans AW, Bertina RM: Thrombophilia: Its causes and a rough estimate of its prevalence. *Thromb Haemost* 58:39, 1987 (abstr)
11. Ben-Tal O, Zivelin A, Seligsohn U: The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. *Thromb Haemost* 61:50, 1989
12. Horellou MH, Conard J, Bertina RM, Samama M: Congenital protein C deficiency and thrombotic disease in nine French families. *Br Med J* 289:1285, 1984
13. Pabinger I, Brucker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K: Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. *Blood Coagul Fibrinolysis* 3:547, 1992
14. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. *Proc Natl Acad Sci USA* 90:1004, 1993
15. Marlar RA, Kleiss AJ, Griffin JH: Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. *Blood* 59:1067, 1982
16. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL: Protein S deficiency in men with long-term human immunodeficiency virus infection. *Blood* 81:1801, 1993
17. Potzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Muller-Berghaus G: Thrombophilia in patients with lupus anticoagulant correlates with impaired anticoagulant activity of activated protein C but not with decreased activation of protein C. *Blood* 80:267a, 1992 (abstr)
18. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G: Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. *N Engl J Med* 325:1565, 1991
19. Schramm W, Spannagi M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP: Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. *Arch Dermatol* 129:753, 1993